

Syngene's Long Term Data

7 years of being a publicly listed company

Revenue (Since listing in 2015)

Revenue: **190%** (INR 1,113 Cr to 3,264 Cr)

PAT

93%

(INR 241 Cr to 464 Cr)

EBITDA

160%

(INR 387 Cr to 1005 Cr)

We touched the **INR 10000 Mn (INR 1000 Cr)**

revenue mark in twenty years; we have more than doubled this figure in the last five to six years – We have almost tripled in the last 7 years

Number of clients (Since listing in 2015)

(From 221 to 450+) **more than doubled**

400

Interesting to note: Client patents recognizing Syngene in the last 20 years

We onboarded **200 clients** during the first two decades; in the last seven years since listing, we have more than doubled the client base to **450+**.

Infrastructure and capacity expansion (Since listing in 2015)

(From 0.9 Mn sq. ft to 2.2 Mn sq. ft) **more than doubled**

Syngene took little over 20 years to build **~1 Mn sq. ft** of infrastructure and we have more than doubled the space in the last seven years **2.2 Mn sq. ft**

Employee base (Since listing in 2015)

3000 to ~8500

We have hired more people in the last five years than the first two decades combined.

New jobs created during the 2 years of the pandemic:

over 1000

New jobs created in FY23

over 1000



Other growth indicators

Market Capitalization
(Since listing in 2015
to March 2023)

284%

Compound annual growth rate
(CAGR) (Since 2016)

17.6%

(15% CAGR over
last 5 years)

Geographical expansion

Research facility in Hyderabad since
2019; Infrastructure more than tripled;
Number of scientists ~900

API manufacturing plant in
Mangalore; received US FDA
regulatory approval in Q1 FY24

Syngene
representatives in
the U.S and Europe

New geographies added since listing (new countries/markets served)

Australia, Brazil, Singapore, Bangladesh, Malaysia, Turkey, Hong Kong, Greece,
Finland, Belgium, Denmark, Croatia, Algeria, Slovenia, Poland, Norway, Argentina,
South Korea, UAE, Saudi Arabia, Hungary, Mexico, Spain, Malta, Japan.

Audits – ‘Anytime Audit Ready’

Reflects high operating standards

In FY23,

~80
successful
client

and regulatory audits +
USFDA, EMA and MHRA of
biologics facilities

Over

120
successful
client

and regulatory audits
in FY21 and FY22 (pandemic years). Approved by regulators in all
the major geographies: US, Europe, Japan, Brazil etc